Trophos is a biopharmaceutical company founded in 1999 to discover and develop new drugs to treat neurodegenerative disorders. Today, Trophos focuses its expertise on two motor neuron diseases, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s Disease) and spinal muscular atrophy (SMA), as well as Huntington’s disease (HD). Trophos has also developed expertise and offers screening services for targets implicated in Alzheimer’s disease.

WHAT IS TRO19622, HOW WAS IT DISCOVERED, WHAT IS ITS DEVELOPMENT STATUS?
TRO19622 is a new chemical entity derived from the Trophos compound collection. The molecule has a cholesterol-like structure and displays remarkable neuroprotective properties both in vitro and in vivo. It was discovered thanks to the original high-throughput screening platform using primary motor neurons that Trophos developed to support its drug discovery strategy. TRO19622 is as effective as a cocktail of three neurotrophic factors in keeping
motor neurons alive in culture. TRO19622 also improves survival of striatal neurons in a cell-based model of Huntington’s disease and displays anti-apoptotic properties for other types of primary neurons. In vivo, TRO19622 is active in several preclinical models of neurodegenerative disease.
Read the full document (PDF file)